Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The German experience in reference pricing.

G Giuliani1, G Selke, L Garattini

  • 1Center for Health Economics CESAV, Mario Negri Institute for Pharmacological Research, Ranica, Italy. cesav@cyberg.it

Health Policy (Amsterdam, Netherlands)
|March 8, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of a New Riluzole-Based Compound VA945 on Sodium and Potassium Conductances Expressed by SH-SY5Y- Derived Neurons.

Journal of neurochemistry·2025
Same author

Non-palpable breast lesions localization techniques - A new priority: Results of a Senonetwork survey among breast centers in Italy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same author

Antibiotic shortages in Europe: Another question of prices?

European journal of internal medicine·2024
Same author

Modeling European health systems: a theoretical exercise.

The European journal of health economics : HEPAC : health economics in prevention and care·2023
Same author

Conceptualizing a model for European health systems: the institutional framework.

Internal and emergency medicine·2023
Same author

Health technology assessment for pharmaceuticals in the European Union: what lessons after two decades?

Internal and emergency medicine·2022
Same journal

Basic human values, responsiveness, and dignity in geriatric organizations in Israel: A qualitative study of state regulations.

Health policy (Amsterdam, Netherlands)·2026
Same journal

A policy analysis of the three-month waiting period for new and returning residents to access provincial health insurance in Ontario, Canada.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Policy priorities in palliative and end-of-life care: An exploration of issues reflected in public strategy.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Advancing stakeholder analysis: Power and participation in health technology assessment policy development in the United Arab Emirates.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Cultural sensitivity concerning the Gaeltacht people of Ireland - a concept analysis.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Israel's 2010 capitation reform and the widening of regional health disparities: A difference-in-differences analysis.

Health policy (Amsterdam, Netherlands)·2026
See all related articles

Germany

Area of Science:

  • Health Economics
  • Pharmaceutical Policy

Background:

  • Public authorities use price regulation schemes for cost containment and to support the national pharmaceutical industry.
  • The dual aims of price regulation create application challenges.
  • Reference pricing, setting price caps for active ingredients, was introduced in Germany in 1989.

Purpose of the Study:

  • To investigate the economic effects of Germany's reference price scheme.
  • To assess the system's effectiveness in controlling public pharmaceutical expenditure.

Main Methods:

  • Analysis of the economic impact of the reference price scheme in Germany.
  • Evaluation of cost containment in public pharmaceutical spending.

Main Results:

Related Experiment Videos

  • The reference price scheme has proven effective in controlling pharmaceutical prices.
  • Overall cost containment in public pharmaceutical expenditure requires additional measures beyond reference pricing.

    • Conclusions:

    • The reference price scheme is a valuable tool for pharmaceutical price control.
    • Further strategies are necessary to achieve comprehensive cost containment in public pharmaceutical expenditure.